JP6770515B2 - Composition for lowering blood pressure - Google Patents

Description

The present invention relates to a composition for lowering blood pressure and the like. More specifically, the present invention relates to a composition for lowering blood pressure containing a heat-treated plant-derived peptide as an active ingredient, the use of a heat-treated plant-derived peptide for lowering blood pressure, and a method for lowering blood pressure using a heat-treated plant-derived peptide. Further, the present invention comprises a composition for suppressing an increase in blood pressure containing a heat-treated plant-derived peptide as an active ingredient, use of a heat-treated plant-derived peptide for suppressing an increase in blood pressure, and blood pressure using a heat-treated plant-derived peptide. It is also related to the method of suppressing the rise of blood pressure.

It is widely known that lifestyle-related diseases such as hypertension and hyperlipidemia are caused by changes in eating habits, lack of exercise, stress, smoking, genetic factors, and the like. In particular, hypertension is characterized by the progression of symptoms without significant subjective symptoms, and shows an extremely high prevalence when the hypertension reserve army is included. In addition, hypertension is serious such as stroke (cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, etc.), heart disease (angina, myocardial infarction, cardiac hypertrophy, heart failure, etc.), and renal failure (hypertensive nephropathy, etc.). It is known to lead to various diseases. Therefore, prevention and early improvement of hypertension are socially required.

Generally, for the improvement of hypertension, drug therapy with a diuretic, angiotensin converting enzyme (ACE) inhibitor, angiotensin receptor antagonist, sympathetic blocker, vasodilator or the like is performed. However, these drug therapies have been reported to be associated with various side effects such as gastric discomfort, diarrhea, and angioedema. Therefore, in order to prevent and improve hypertension, it is desired to develop a safe and long-term ingestible active ingredient.

For example, Patent Document 1 discloses that a peptide mixture obtained by decomposing fish meat or soybean with a plant-derived thiol protease has an angiotensin converting enzyme inhibitory effect. Further, Patent Document 2 discloses that functional foods and pharmaceuticals containing a soybean proteolytic mixture obtained by enzymatically decomposing heat-denatured soybean protein have an antihypertensive effect. Further, Patent Document 3 discloses that a hydrolyzate obtained by treating soybean whey protein with a protease or a fraction thereof has an angiotensin converting enzyme inhibitory effect. However, in the examples reported so far, there has been a problem that complicated treatment steps such as enzyme treatment, fractionation, and concentration of raw materials are required. Therefore, there is a demand for the development of a composition for lowering blood pressure and a composition for suppressing increase in blood pressure, which can be produced more easily and are highly effective.

Japanese Unexamined Patent Publication No. 62-169732 Japanese Unexamined Patent Publication No. 2003-210138 Japanese Patent No. 4797627

The subject of the present invention is a composition for lowering blood pressure, which can be produced more easily and has a higher effect than a known plant-derived peptide-containing material, the use of a material for lowering blood pressure, and a method for lowering blood pressure. To provide. Furthermore, it is also an object of the present invention to provide a composition for suppressing an increase in blood pressure that can be easily produced and has a high effect, the use of a material for suppressing the increase in blood pressure, and a method for suppressing the increase in blood pressure. ..

As a result of diligent studies in view of the above problems, the present inventors have compared a heat-treated plant-derived peptide obtained by heat-treating a plant-derived peptide at a temperature exceeding 100 ° C. with a non-heated plant-derived peptide. It was found to have a stronger antihypertensive effect. As a result, it is considered that the plant-derived peptide heat-treated product has a preventive or ameliorating effect on hypertension and a preventive or ameliorating effect on various diseases caused by hypertension such as stroke, heart disease and renal failure. Has been completed.

That is, the present invention relates to the following, but is not limited thereto.
(1) A composition for lowering blood pressure or a composition for suppressing increase in blood pressure, which contains a heat-treated plant-derived peptide as an active ingredient.
The composition, wherein the total amount of the cyclic dipeptide of the plant-derived peptide heat-treated product or a salt thereof is 20000 μg / 100 g / Brix or more.
(2) The composition for lowering blood pressure or the composition for suppressing increase in blood pressure according to (1), wherein the total amount of the cyclic dipeptide of the heat-treated plant-derived peptide or a salt thereof is 30,000 μg / 100 g / Brix or more.
(3) The composition for lowering blood pressure or the composition for suppressing increase in blood pressure according to (1) or (2), wherein the heat-treated plant-derived peptide is a high-temperature and high-pressure treated product of a plant-derived peptide.
(4) The product according to any one of (1) to (3), wherein the heat-treated plant-derived peptide is obtained by treating a plant-derived peptide at a temperature exceeding 100 ° C. and a pressure of 0.101 MPa or more at high temperature and high pressure. A composition for lowering blood pressure or a composition for suppressing increase in blood pressure.
(5) The composition for lowering blood pressure or the composition for suppressing increase in blood pressure according to any one of (1) to (4), wherein the high-temperature and high-pressure treated product is obtained by high-temperature and high-pressure treatment for 3 hours or more.
(6) The composition for lowering blood pressure or the composition for suppressing increase in blood pressure according to any one of (1) to (5), wherein the plant-derived peptide is a soybean peptide, a tea peptide, or a malt peptide.
(7) The composition for lowering blood pressure or the composition for suppressing increase in blood pressure according to any one of (1) to (5), wherein the plant-derived peptide is a soybean peptide.
(8) The composition for lowering blood pressure or the composition for suppressing increase in blood pressure according to any one of (1) to (7), which is used for preventing or improving hypertension.
(9) The composition for lowering blood pressure or the composition for suppressing increase in blood pressure according to any one of (1) to (7), which is used for preventing or ameliorating stroke, heart disease, or renal failure.
(10) The composition for lowering blood pressure or the composition for suppressing increase in blood pressure according to any one of (1) to (9), which is labeled with a function exerted by lowering blood pressure or suppressing the increase in blood pressure.
(11) Function indications are "lower blood pressure", "expect lower blood pressure", "suppress blood pressure rise", "moderate blood pressure rise", "sudden rise in blood pressure when waking up" It is selected from the group consisting of "suppressing", "preventing hypertension", "helping to improve hypertension", "protecting renal function", and "improving renal function". Item 3. The composition for lowering blood pressure or the composition for suppressing increase in blood pressure according to Item 10.
(12) Use of a plant-derived peptide heat-treated product for lowering blood pressure or suppressing an increase in blood pressure.
The above-mentioned use, wherein the total amount of the cyclic dipeptide of the plant-derived peptide heat-treated product or a salt thereof is 20000 μg / 100 g / Brix or more.
(13) The use according to (12), wherein the plant-derived peptide is a soybean peptide, a tea peptide, or a malt peptide.
(14) The use according to (12), wherein the plant-derived peptide is a soybean peptide.
(15) A method of lowering blood pressure or suppressing an increase in blood pressure by using a heat-treated plant-derived peptide as an active ingredient.
The method as described above, wherein the total amount of the cyclic dipeptide of the plant-derived peptide heat-treated product or a salt thereof is 20000 μg / 100 g / Brix or more.
(16) The method according to (15), wherein the plant-derived peptide is a soybean peptide, a tea peptide, or a malt peptide.
(17) The method according to (15), wherein the plant-derived peptide is a soybean peptide.

In the present invention, it is possible to provide a composition having a stronger antihypertensive effect and an effect of suppressing an increase in blood pressure as compared with a known plant-derived peptide-containing material by a simple processing technique of high-temperature and high-pressure treatment. Since the heat-treated plant-derived peptide contained in the composition of the present invention is highly safe, it can be said that the composition of the present invention has high utility value in the market. In addition, by ingesting the composition of the present invention, the effect of preventing or ameliorating hypertension and the effect of preventing or ameliorating various diseases caused by hypertension such as stroke, heart disease and renal failure are exhibited.

FIG. 1 shows the time course of systolic blood pressure after administration of soybean peptide or soybean peptide heat-treated product to spontaneously hypertensive rats.

One aspect of the present invention is a composition for lowering blood pressure containing a heat-treated plant-derived peptide as an active ingredient. The present invention is also a composition for suppressing an increase in blood pressure, which contains a heat-treated plant-derived peptide as an active ingredient.

1. 1. Plant-derived peptides In the present specification, "plant-derived peptides" are defined as plant-derived proteins or decomposition treatments known to plants containing proteins (decomposition treatment by heat or pressure, decomposition treatment by acid or alkali) unless otherwise specified. , Degradation treatment with an enzyme, etc.) to reduce the molecular weight of the peptide.

The plant-derived peptide of the present invention may be a plant-derived protein or one type of peptide obtained from a plant containing the protein, or may be a mixture of two or more types of peptides. The number of amino acids constituting the plant-derived peptide is not particularly limited, but is preferably 2 to several tens, and more preferably 2 to several (that is, oligopeptide).

In the present invention, the plant-derived peptide preferably has a high proportion of peptides having a molecular weight of 5000 or less, more preferably has a high proportion of peptides having a molecular weight of 3000 or less, and has a high proportion of peptides having a molecular weight of 1000 or less. It is particularly preferable to use one. Here, "high proportion of peptide" means a state in which at least 50% of all plant-derived peptides correspond to the peptide. The measurement of the molecular weight can be carried out by using a method and an apparatus (HPLC, etc.) well known to those skilled in the art.

The plant-derived peptide of the present invention is not particularly limited, but a plant-derived peptide such as beans, leaves, seeds, or potatoes is preferably used. Examples of beans include soybeans, adzuki beans, black beans and the like. Examples of the leaves include tea leaves (green tea leaves, black tea leaves, oolong tea leaves) and the like. Examples of seeds include barley, wheat (including wheat germ), malt, sesame seeds, rice and the like. Examples of potatoes include sweet potatoes and potatoes. Among these plants, soybean, tea leaves and malt are preferable in the present invention, and soybean is more preferable. In this specification, the description of "derived" may be omitted for a plant-derived peptide derived from a specific plant. For example, in the case of "soybean-derived peptide", this may be referred to as "soybean peptide". At this time, both are used interchangeably.

The plant-derived peptide can be obtained by decomposing a plant-derived protein or a plant containing the protein by a conventionally known method. Examples of such decomposition treatments include decomposition treatments with heat and pressure, decomposition treatments with acids and alkalis, and decomposition treatments with enzymes. In any of the treatments, water, ethanol, or the like can be used as a solvent. For example, in the case of decomposition treatment by heating, conditions of 30 minutes to several hours at a temperature of 100 ° C. or higher are shown. It should be noted that this heat treatment can be performed at the same time as the heat treatment of the above-mentioned plant-derived peptide heat-treated product. Further, in the case of decomposition treatment with an enzyme, various proteolytic enzymes (proteases) can be appropriately used depending on the purpose.

As the plant-derived peptide, one prepared by oneself using a known method may be used, or a commercially available product may be used. Examples of commercially available plant-derived peptides include soy peptides such as High Newt AM, High Newt DC, and High Newt HK (manufactured by Fuji Oil Co., Ltd.), and rice peptides such as Oryza Peptide-P60 (manufactured by Oryza Oil Chemicals Co., Ltd.). Examples thereof include wheat peptides such as glutamine peptide GP-1N and glutamine peptide GP-N (manufactured by Nisshin Pharma Co., Ltd.), and sesame peptides such as sesame peptide KM-20 (manufactured by KISCO).

2. Heat-treated plant-derived peptide The heat-treated plant-derived peptide is obtained by heat-treating a plant-derived peptide in a liquid at a high temperature. The high-temperature heat treatment is not particularly limited, but the treatment is preferably performed under conditions that include not only high-temperature conditions but also high-pressure conditions. Therefore, in the present specification, the "plant-derived peptide heat-treated product" may be a high-temperature heat-treated product of a plant-derived peptide or a high-temperature and high-pressure treated product. Pure water can be preferably used as the liquid in the high-temperature heat treatment and the high-temperature high-pressure treatment, but an organic solvent such as ethanol can be appropriately contained therein. Further, the hardness can be appropriately adjusted by adding a mineral component to the extraction solvent.

As used herein, the term "high temperature heat treatment" means treatment at a temperature exceeding 100 ° C. and a pressure exceeding atmospheric pressure for a certain period of time. As the high-temperature and high-pressure processing device, a pressure-resistant extraction device, a pressure cooker, an autoclave, or the like can be used according to the conditions.

The temperature in the high temperature heat treatment is not particularly limited as long as it exceeds 100 ° C., but is preferably 105 ° C. or higher, 110 ° C. or higher, 115 ° C. or higher, 120 ° C. or higher, 125 ° C. or higher, 130 ° C. or higher, or 135 ° C. or higher. Is. The temperature is preferably 170 ° C. or lower, 165 ° C. or lower, 160 ° C. or lower, 155 ° C. or lower, 150 ° C. or lower, 145 ° C. or lower, or 140 ° C. or lower. Typically, the temperature is 105 ° C to 170 ° C, preferably 110 ° C to 150 ° C, more preferably 120 ° C to 140 ° C. This temperature indicates the measured value of the outlet temperature of the extraction column when a pressure-resistant extraction device is used as the heating device, and the temperature of the center temperature in the pressure vessel when an autoclave is used as the heating device. Shows the measured value.

The high-temperature and high-pressure pressure is not particularly limited as long as it exceeds the atmospheric pressure, but is preferably 0.101 MPa or more, 0.15 MPa or more, 0.2 MPa or more, 0.25 MPa or more, or 0.3 MPa or more. The pressure is preferably 0.79 MPa or less, 0.75 MPa or less, 0.7 MPa or less, 0.65 MPa or less, 0.6 MPa or less, 0.55 MPa or less, 0.5 MPa or less, 0.48 MPa or less. Typically, the pressure is 0.101 MPa to 0.79 MPa, preferably 0.101 MPa to 0.60 MPa, more preferably 0.101 MPa to 0.48 MPa.

The high-temperature heat treatment time is not particularly limited as long as the desired processed product can be obtained, but is preferably 10 minutes or more, 15 minutes or more, 30 minutes or more, 60 minutes or more, 120 minutes or more, or 180 minutes or more. The high temperature heat treatment time is preferably 600 minutes or less, 500 minutes or less, 400 minutes or less, 300 minutes or less, or 200 minutes or less. Typically, the high temperature heat treatment time is preferably about 10 minutes to 600 minutes, about 30 minutes to 500 minutes, about 60 minutes to 400 minutes, or about 180 minutes to 300 minutes.

In the present invention, more suitable high-temperature treatment conditions for obtaining a heat-treated plant-derived peptide are, for example, in a coordinate system in which the horizontal axis is time (min.) And the vertical axis is temperature (° C.), the following coordinate system (i). )-(Vi) is a high temperature treatment that is maintained within the time and temperature range. (I) (170 ℃, 30min.), (Ii) (150 ℃, 30min.), (Iii) (115 ℃, 180min.), (Iv) (105 ℃, 480min.), (V) (135 ℃) , 480min.), (Vi) (150 ℃, 180min.)
The treatment conditions regarding the temperature, pressure and time of the plant-derived peptide for obtaining the heat-treated plant-derived peptide are not particularly limited, but can be set as follows, for example:
(Temperature, pressure, time) =
(105 ° C to 170 ° C, 0.101 MPa to 0.79 MPa, 15 minutes to 600 minutes),
(105 ° C to 170 ° C, 0.101 MPa to 0.79 MPa, 30 minutes to 500 minutes),
(105 ° C to 170 ° C, 0.101 MPa to 0.79 MPa, 60 minutes to 300 minutes),
(105 ° C to 170 ° C, 0.15 MPa to 0.48 MPa, 15 minutes to 600 minutes),
(105 ° C to 170 ° C, 0.15 MPa to 0.48 MPa, 30 minutes to 500 minutes),
(105 ° C to 170 ° C, 0.15 MPa to 0.48 MPa, 60 minutes to 300 minutes),
(110 ° C to 150 ° C, 0.101 MPa to 0.79 MPa, 15 minutes to 600 minutes),
(110 ° C to 150 ° C, 0.101 MPa to 0.79 MPa, 30 minutes to 500 minutes),
(110 ° C to 150 ° C, 0.101 MPa to 0.79 MPa, 60 minutes to 300 minutes),
(110 ° C to 150 ° C, 0.15 MPa to 0.48 MPa, 15 minutes to 600 minutes),
(110 ° C to 150 ° C, 0.15 MPa to 0.48 MPa, 30 minutes to 500 minutes),
(110 ° C to 150 ° C, 0.15 MPa to 0.48 MPa, 60 minutes to 300 minutes),
(120 ° C to 140 ° C, 0.101 MPa to 0.79 MPa, 15 minutes to 600 minutes),
(120 ° C to 140 ° C, 0.101 MPa to 0.79 MPa, 30 minutes to 500 minutes),
(120 ° C to 140 ° C, 0.101 MPa to 0.79 MPa, 60 minutes to 300 minutes),
(120 ° C to 140 ° C, 0.15 MPa to 0.48 MPa, 15 minutes to 600 minutes),
(120 ° C to 140 ° C, 0.15 MPa to 0.48 MPa, 30 minutes to 500 minutes),
(120 ° C to 140 ° C, 0.15 MPa to 0.48 MPa, 60 minutes to 300 minutes) and the like.

In the present invention, the heat-treated plant-derived peptide can be prepared using an apparatus capable of providing the above-mentioned treatment conditions. Examples of such a device include, but are not limited to, a pressure-resistant extraction device, a pressure cooker, an autoclave, etc., which are well known to those skilled in the art. Further, the plant-derived peptide heat-treated product may be one obtained by solid-liquid separation before and / or after the heat treatment. The liquid part can be recovered by performing the solid-liquid separation process, and it becomes possible to handle only the solid. For solid-liquid separation, means such as filtrate and / or centrifugation are used. Further, the plant-derived peptide heat-treated product may be one that has been further subjected to a purification treatment after the heat treatment. By performing the purification treatment, a specific component contained in the heat-treated plant-derived peptide can be concentrated. The purification treatment of the heat-treated plant-derived peptide can be performed using a known method and apparatus. In addition, the plant-derived peptide heat-treated product may be further subjected to a clarification treatment before and / or after the heat treatment. The clarification treatment can be carried out using a known method and apparatus, and the treatment can increase the degree of freedom in designing a composition to which a plant-derived peptide heat-treated product is added. Moreover, the plant-derived peptide heat-treated product may be freeze-dried or powdered using a known method and apparatus. In addition, as a method for producing a heat-treated plant-derived peptide product in the present invention, the method described in International Publication No. 2014/200,000 can be referred to.

3. 3. Cyclic dipeptide or salt thereof The plant-derived peptide heat-treated product is obtained by high-temperature heat treatment or high-temperature high-pressure treatment of the plant-derived peptide, and a large amount of cyclic dipeptide or its salt is contained in the plant-derived peptide heat-treated product by the treatment. Will come to be. That is, in the present invention, the heat-treated plant-derived peptide contains a cyclic dipeptide or a salt thereof as one of its characteristics. Although it is not desired to be bound by a specific theory, since the heat-treated plant-derived peptide contains a large amount of cyclic dipeptide or a salt thereof, the cyclic dipeptide or its salt is a composition for lowering blood pressure or an increase in blood pressure. It can be the active ingredient of the inhibitory composition. In addition, in this specification, a cyclic dipeptide or a salt thereof may be collectively referred to as a cyclic dipeptide.

The cyclic dipeptide referred to in the present specification is a dipeptide having a diketopiperazine structure produced by dehydration condensation of an amino group and a carboxyl group of an amino acid, which is characterized by having an amino acid as a constituent unit. Therefore, cyclic dipeptides are distinguished from linear dipeptides.

Cyclic dipeptides include any combination of amino acids, and the two amino acids may be the same or different. The type of cyclic dipeptide is not particularly limited, but is, for example, cycloalanylglutamine (CAS Registry Number: 268221-76-7; Cyclo (Ala-Gln)), cyclohistidylproline (CAS Registry Number: 53109-32). -3; Cyclo (His-Pro)), Cycloalaninealanine (CAS Registry Number: 5845-61-4; Cyclo (Ala-Ala)), Cycloglycylproline (CAS Registry Number: 3705-27-9; Cyclo (Gly-Pro)), Cycloceryltyrosine (CAS Registry Number: 21754-31-4; Cyclo (Ser-Tyr)), Cycloprolylsleonine (CAS Registry Number: 227777-31-3; Cyclo (Pro-Thr)) ), Cyclohistidylphenylalanine (CAS Registry Number: 56586-95-9; Cyclo (His-Phe)), Cycloalanylproline (CAS Registry Number: 65556-33-4; Cyclo (Ala-Pro)), Cyclo Phenylalanine Serine (CAS Registry Number: 35591-00-5; Cyclo (Phe-Ser)), Cycloglycyl Leucine (CAS Registry Number: 5845-67-0; Cyclo (Gly-Leu)), Cycloglycylphenylalanine (CAS Registry Number: 10125-07-2; Cyclo (Gly-Phe)), Cycloprolyl Proline (Cyclo (Pro-Pro)), Cycloglycyltryptophan (Cyclo (Gly-Trp)), Cycloaspartylphenylalanine ( CAS Registry Number: 5262-10-2; Cyclo (Asp-Phe)), Cyclovalylproline (Cyclo (Val-Pro)), Cycloprolyl tyrosine (Cyclo (Pro-Tyr)), Cyclomethionylproline (Cyclo (Cyclo (Val-Pro)) Met-Pro)), Cyclomethionylmethionine (Cyclo (Met-Met)), Cyclovalylvalin (Cyclo (Val-Val)), Cycloleucylproline (CAS Registry Number: 2873-36-1; Cyc lo (Leu-Pro)), Cyclotryptophanyltyrosine (Cyclo (Trp-Tyr)), Cyclophenylalanylproline (CAS Registry Number: 3705-26-8; Cyclo (Phe-Pro)), Cycloleucyltryptophan (CAS Registry Number: 15136-34-2; Cyclo (Leu-Trp)), Cyclophenylalanyl tryptophan (CAS Registry Number: 82397-82-8; Cyclo (Phe-Trp)), Cycloleuylphenylalanine (CAS Registry) Number: 7280-77-5; Cyclo (Leu-Phe)), Cycloleucylleucine (CAS Registry Number: 952-45-4; Cyclo (Leu-Leu)), Cyclophenylalanylphenylalanine (CAS Registry Number: 2862) -51-3; Cyclo (Phe-Phe)) and the like. The cyclic dipeptide may be only one kind or a combination of two or more kinds. Regarding the cyclic dipeptide, as long as the composition of the two types of amino acids is the same, the description order of them may be any first. For example, [Cyclo (Pro-Hyp)] and [Cyclo (Hyp-Pro)] are It represents the same cyclic dipeptide.

Salts of cyclic dipeptides include any pharmacologically acceptable salt, including inorganic and organic salts. Such salts include, for example, sodium salts, potassium salts, calcium salts, magnesium salts, ammonium salts, hydrochlorides, sulfates, nitrates, phosphates, organic acid salts (acetate, citrate, maleate, etc.) Examples thereof include malate, oxalate, lactate, succinate, fumarate, propionate, nitate, benzoate, picphosphate, benzenesulfonate, trifluoroacetate, etc.). , Not limited to these.

The amount of the cyclic dipeptide or a salt thereof contained in the heat-treated plant-derived peptide varies depending on the type of the heat-treated plant-derived peptide and is not particularly limited. For example, its content is Cyclo (Ala-Gln), Cyclo (Ala-Ala), Cyclo (Ser-Tyr), Cyclo (Gly-Trp), Cyclo (Val-Val), Cyclo (Trp-Tyr), Cyclo. Any one or more of (Leu-Trp) and Cyclo (Phe-Phe) has a content of 10 μg / 100 g / Brix or more per Brix. As another example, the total amount of the cyclic dipeptide or a salt thereof contained in the plant-derived peptide heat-treated product in the present invention is preferably 20000 μg / 100 g / Brix or more, 25000 μg / 100 g / Brix as the content per Brix. As mentioned above, it is 30,000 μg / 100 g / Brix or more, more preferably 35,000 μg / 100 g / Brix or more. The total amount is preferably 500 mg / 100 g / Brix or less, 400 mg / 100 g / Brix or less, 300 mg / 100 g / Brix or less, and more preferably 200 mg / 100 g / Brix or less. Typically, the total amount of the cyclic dipeptide or salt thereof contained in the plant-derived peptide heat-treated product in the present invention is preferably 20000 μg / 100 g / Brix to 500 mg / 100 g / Brix, and more preferably 30,000 μg / 100 g / Brix to 400 mg /. It is 100 g / Brix, and even more preferably 35000 μg / 100 g / Brix to 300 mg / 100 g / Brix. When the cyclic dipeptide is in the form of a salt, the above content shall be calculated after converting to a free form. In this specification, unless otherwise specified, the total amount of the cyclic dipeptide or a salt thereof represents the total value of any cyclic dipeptide represented by Cyclo (X-Y). However, X and Y are glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, glutamic acid, aspartic acid, glutamine, arginine, lysine, cysteine, methionine, phenylalanine, tyrosine, tryptophan, histidine, proline, hydroxyproline, etc. It is an arbitrary amino acid selected from the group consisting of, and X and Y may be the same or different.

In the present specification, the "content per Brix" means an amount determined by a value corresponding to the mass percentage of a sucrose solution (an aqueous solution containing only sucrose as a solute) at 20 ° C. The content of the cyclic dipeptide or a salt thereof per Brix can be measured with a commercially available Brix measuring instrument.

Preferable embodiments of the plant-derived peptide heat-treated product in the present invention include a soybean peptide heat-treated product, a tea peptide heat-treated product, and a malt peptide heat-treated product. Hereinafter, these heat-treated products will be described in detail.

3-1. Soybean peptide heat-treated soybean (scientific name: Glycine max) can be used without restrictions on varieties and production areas, and processed products such as crushed products can also be used. Protein in soybeans is said to account for about 30%. Unlike tea leaf protein, soybean protein does not contain many water-insoluble proteins, so pretreatment for removing water-soluble protein is not essential and may be performed as needed. If there is no pretreatment to remove the water-soluble protein, a one-pot reaction can more easily produce a heat-treated soybean peptide containing a high concentration of cyclic dipeptide.

The soybean peptide heat-treated product in the present invention is a cyclic dipeptide that was not contained in the conventional soybean proteolytic product (soybean peptide), such as Cyclo (Ala-Gln), Cyclo (Ala-Ala), and Cyclo (Ser-Tyr). , Cyclo (Gly-Trp), Cyclo (Val-Val), Cyclo (Trp-Tyr), Cyclo (Leu-Trp) and Cyclo (Phe-Phe) with a content of 10 μg / 100 g / per Brix. It is contained in Brix or higher.

The soybean peptide heat-treated product in the present invention includes Cyclo (Ala-Gln), Cyclo (His-Pro), Cyclo (Ala-Ala), Cyclo (Gly-Pro), Cyclo (Ser-Tyr), and Cyclo (Pro-). Thr), Cyclo (His-Phe), Cyclo (Ala-Pro), Cyclo (Phe-Ser), Cyclo (Gly-Leu), Cyclo (Gly-Phe), Cyclo (Gly-Trp), Cyclo (Asp-Phe) ), Cyclo (Val-Pro), Cyclo (Pro-Tyr), Cyclo (Met-Pro), Cyclo (Val-Val), Cyclo (Leu-Pro), Cyclo (Trp-Tyr), Cyclo (Phe-Pro) , Cyclo (Leu-Trp), Cyclo (Leu-Phe), Cyclo (Leu-Leu) and Cyclo (Phe-Phe), respectively, at a concentration of 0.1 ppm / Brix (10 μg / 100 g / Brix) or more. Preferably, each of the above cyclic dipeptides is 0.5 ppm / Brix or more, more preferably 0.7 ppm / Brix or more, still more preferably 0.9 ppm / Brix or more, particularly preferably 1.0 ppm / Brix or more, and particularly preferably 1. It is a soybean peptide heat-treated product contained at a concentration of 2 ppm / Brix or more. Further, Cyclo (Leu-Leu), Cyclo (Leu-Phe), Cyclo (Ser-Tyr) and Cyclo (Pro-Thr) are each 0.1 ppm / Brix (10 μg / 100 g / Brix) or more, preferably 0. It can be contained at a concentration of 2 ppm / Brix or more, more preferably 0.3 ppm / Brix or more.

This heat-treated soybean peptide (particularly, a heat-treated product obtained from soybean or a pulverized product thereof) is Cyclo (Leu-Pro), Cyclo (Phe-Pro) and Cyclo (Leu) known as cyclic dipeptides having a strong bitterness. Despite containing -Trp), its bitterness is reduced. When an aqueous solution containing the same concentration of Cyclo (Leu-Pro) and Cyclo (Phe-Pro) was prepared, strong bitterness was felt, so other coexisting cyclic dipeptides and soybean-derived components were added. It is considered that the bitterness of Cyclo (Leu-Pro), Cyclo (Phe-Pro) and Cyclo (Leu-Trp) is alleviated objectively or synergistically. In particular, the total amount (B) of the cyclic dipeptides Cyclo (Leu-Pro), Cyclo (Phe-Pro) and Cyclo (Leu-Trp) having a bitter taste with respect to the total amount (A) of Cyclo (Leu-Leu) and Cyclo (Leu-Phe). ) Is 1.0 or less (preferably 0.8 or less, more preferably 0.6 or less, particularly preferably 0.5 or less) of the soybean peptide heat-treated product having a ratio of [(B) / (A)]. It is a cyclic dipeptide-containing heat-treated product with significantly reduced bitterness, and can be applied orally.

The total amount of the cyclic dipeptide or a salt thereof per Brix in the heat-treated soybean peptide in the present invention is preferably 20000 μg / 100 g / Brix or more, 25000 μg / 100 g / Brix or more, 30,000 μg / 100 g / Brix or more, and more preferably 35000 μg / 100 g. / Brix or higher. The total amount is preferably 500 mg / 100 g / Brix or less, 400 mg / 100 g / Brix or less, 300 mg / 100 g / Brix or less, and more preferably 200 mg / 100 g / Brix or less. Typically, the total amount of cyclic dipeptide or salt thereof per Brix in the soybean peptide heat-treated product of the present invention is preferably 20000 μg / 100 g / Brix to 500 mg / 100 g / Brix, more preferably 30,000 μg / 100 g / Brix to 400 mg. / 100 g / Brix, and even more preferably 35000 μg / 100 g / Brix to 300 mg / 100 g / Brix.

The heat-treated soybean peptide product in the present invention preferably contains Cyclo (Leu-Leu), Cyclo (Leu-Phe), Cyclo (Ser-Tyr) and Cyclo (Pro-Thr) in high concentrations. In the heat-treated soybean peptide, these concentrations are 5.0 ppm / Brix (500 μg / 100 g / Brix) or more, preferably 6.0 ppm / Brix or more, and more preferably 7.0 ppm / Brix or more. In particular, the content of Cyclo (Leu-Leu) and Cyclo (Leu-Phe) is preferably 10.0 ppm / Brix or more, preferably 12.0 ppm / Brix or more. These upper limits are 50.0 ppm / Brix or less, preferably 40.0 ppm / Brix or less, more preferably 35.0 ppm / Brix or less, still more preferably about 30.0 ppm / Brix or less. Unless otherwise specified, "ppm" used in the present specification means ppm of weight / volume (w / v).

3-2. As the tea leaves used as the extraction raw material for the tea peptide heat-treated product , extracted and drinkable parts such as tea leaves and stems produced using tea plant (scientific name: Camellia sinensis) can be used. In addition, its morphology is not limited to perilla or powder. The harvest time of tea leaves can also be appropriately selected according to the desired flavor.

The tea peptide heat-treated product of the present invention is characterized in that by producing it without going through a fermentation process, the formation of by-products is suppressed and a product having a good flavor can be obtained. From the viewpoint of this flavor, tea leaves include steamed non-fermented tea (green tea) such as sencha, bancha, roasted tea, tamaro, kabusecha, and jincha, and pot-roasted tea such as Ureshino tea, Aoyagi tea, and various Chinese teas. It is preferable to use unfermented tea.

On the other hand, the tea peptide heat-treated product in the present invention is a cyclic dipeptide that was not contained in conventional teas, such as Cyclo (Ala-Gln), Cyclo (Ala-Ala), Cyclo (Ser-Tyr), and Cyclo (Gly). -Any one or more of Trp), Cyclo (Val-Val), Cyclo (Trp-Tyr), Cyclo (Leu-Trp) and Cyclo (Phe-Phe) is contained at a concentration of 10 μg / 100 g / Brix or more.

The tea leaf peptide heat-treated product in the present invention includes Cyclo (Ala-Gln), Cyclo (His-Pro), Cyclo (Ala-Ala), Cyclo (Gly-Pro), Cyclo (Ser-Tyr), and Cyclo (Pro-). Thr), Cyclo (His-Phe), Cyclo (Ala-Pro), Cyclo (Phe-Ser), Cyclo (Gly-Leu), Cyclo (Gly-Phe), Cyclo (Pro-Pro), Cyclo (Asp-Phe) ), Cyclo (Val-Pro), Cyclo (Pro-Tyr), Cyclo (Met-Pro), Cyclo (Leu-Pro), Cyclo (Phe-Pro), Cyclo (Leu-Phe), and Cyclo (Leu-Leu) ) Is contained at a concentration of 0.1 ppm / Brix (10 μg / 100 g / Brix) or more, respectively. Tea leaves preferably containing each of the above cyclic dipeptides at a concentration of 0.2 ppm / Brix or more, more preferably 0.3 ppm / Brix or more, still more preferably 0.4 ppm / Brix or more, and particularly preferably 0.5 ppm / Brix or more. It is a peptide heat-treated product. Furthermore, Cyclo (Gly-Trp), Cyclo (Val-Val), Cyclo (Trp-Tyr), Cyclo (Leu-Trp), Cyclo (Phe-Trp) and Cyclo (Phe-Phe) are each 0.1 ppm / It can be contained at a concentration of Brix (10 μg / 100 g / Brix) or more, preferably 0.2 ppm / Brix or more, and more preferably 0.3 ppm / Brix or more.

The total amount of the cyclic dipeptide or a salt thereof per Brix in the heat-treated tea peptide in the present invention is preferably 20000 μg / 100 g / Brix or more, 25000 μg / 100 g / Brix or more, 30000 μg / 100 g / Brix or more, more preferably 35000 μg / 100 g. / Brix or higher. The total amount is preferably 500 mg / 100 g / Brix or less, 400 mg / 100 g / Brix or less, 300 mg / 100 g / Brix or less, and more preferably 200 mg / 100 g / Brix or less. Typically, the total amount of cyclic dipeptide or salt thereof per Brix in the tea peptide heat-treated product of the present invention is preferably 20000 μg / 100 g / Brix to 500 mg / 100 g / Brix, more preferably 30,000 μg / 100 g / Brix to 400 mg. / 100 g / Brix, and even more preferably 35000 μg / 100 g / Brix to 300 mg / 100 g / Brix.

The tea peptide heat-treated product in the present invention preferably contains Cyclo (Leu-Leu), Cyclo (Leu-Phe), and Cyclo (Ala-Ala) in high concentrations. When these are expressed in concentrations, they are tea peptide heat-treated products having a concentration of 5.0 ppm / Brix (500 μg / 100 g / Brix) or more, preferably 8.0 ppm / Brix or more, and more preferably 10.0 ppm / Brix or more. .. These upper limits are 50.0 ppm / Brix or less, preferably 40.0 ppm / Brix or less, more preferably 35.0 ppm / Brix or less, still more preferably about 30.0 ppm / Brix or less.

3-3. Malt, which is a raw material for heat-treated malt peptides, can be used without restrictions on varieties and production areas, but barley malt obtained by germinating barley seeds is particularly preferably used. In the present specification, barley malt may be simply referred to as "malt". It is practical and efficient to remove the skin of barley malt and separate the fractions having a high protein content. Examples of the protein-rich fraction include a method in which malt is gradually scraped from the surface to remove the grain skin, and then the protein-rich fraction such as the aleurone layer and endosperm is scraped. Alternatively, a pre-extracted extraction residue can be used, such as a heat-treated tea leaf peptide. As the extraction residue, squeezed meal of malt generated during beer production can be exemplified.

If a fraction having a high protein content is used as a raw material, a heat-treated malt peptide containing a high concentration of cyclic dipeptide can be more easily produced by a one-pot reaction.

The heat-treated malt peptide in the present invention is a cyclic dipeptide that has been difficult to extract in the past, such as Cyclo (Ala-Gln), Cyclo (Ala-Ala), Cyclo (Ser-Tyr), Cyclo (Gly-Trp), and Cyclo (Val). -Val), Cyclo (Trp-Tyr), Cyclo (Leu-Trp) and Cyclo (Phe-Phe) are contained at a concentration of 10 μg / 100 g / Brix or more.

The heat-treated malt peptide in the present invention includes Cyclo (Ala-Gln), Cyclo (His-Pro), Cyclo (Ala-Ala), Cyclo (Gly-Pro), Cyclo (Ser-Tyr), and Cyclo (Pro-). Thr), Cyclo (His-Phe), Cyclo (Ala-Pro), Cyclo (Phe-Ser), Cyclo (Gly-Leu), Cyclo (Gly-Phe), Cyclo (Gly-Trp), Cyclo (Asp-Phe) ), Cyclo (Val-Pro), Cyclo (Pro-Tyr), Cyclo (Met-Pro), Cyclo (Val-Val), Cyclo (Leu-Pro), Cyclo (Trp-Tyr), Cyclo (Phe-Pro) , Cyclo (Leu-Trp), Cyclo (Leu-Phe), Cyclo (Leu-Leu) and Cyclo (Phe-Phe) are contained at concentrations of 0.1 ppm / Brix (50 μg / 100 g / Brix) or more, respectively. The malt peptide heat-treated product preferably contains each of the above cyclic dipeptides at 0.3 ppm / Brix or more, more preferably 0.4 ppm / Brix or more, still more preferably 0.5 ppm / Brix or more, and particularly preferably 0.6 ppm / Brix or more. It is contained in the concentration of.

Although the heat-treated malt peptide in the present invention contains Cyclo (Leu-Pro), Cyclo (Phe-Pro) and Cyclo (Leu-Trp), which are known as cyclic dipeptides having a strong bitterness, the bitterness is It has been reduced. In particular, the total amount (B) of the cyclic dipeptides Cyclo (Leu-Pro), Cyclo (Phe-Pro) and Cyclo (Leu-Trp) having a bitter taste with respect to the total amount (A) of Cyclo (Leu-Leu) and Cyclo (Leu-Phe). The malt peptide heat-treated product having a ratio [(B) / (A)] of 1.0 or less (preferably 0.8 or less) is a cyclic dipeptide-containing heat-treated product in which bitterness is significantly reduced, and is oral. Applicable.

The total amount of the cyclic dipeptide or a salt thereof per Brix in the heat-treated malt peptide in the present invention is preferably 20000 μg / 100 g / Brix or more, 25000 μg / 100 g / Brix or more, 30,000 μg / 100 g / Brix or more, more preferably 35000 μg / 100 g. / Brix or higher. The total amount is preferably 500 mg / 100 g / Brix or less, 400 mg / 100 g / Brix or less, 300 mg / 100 g / Brix or less, and more preferably 200 mg / 100 g / Brix or less. Typically, the total amount of cyclic dipeptide or salt thereof per Brix in the malt peptide heat-treated product of the present invention is preferably 20000 μg / 100 g / Brix to 500 mg / 100 g / Brix, more preferably 30,000 μg / 100 g / Brix to 400 mg. / 100 g / Brix, and even more preferably 35000 μg / 100 g / Brix to 300 mg / 100 g / Brix.

The malt peptide heat-treated product in the present invention preferably contains Cyclo (Leu-Leu), Cyclo (Leu-Phe) and Cyclo (Ala-Ala) in high concentrations. Specifically, these concentrations are 5.0 ppm / Brix (500 μg / 100 g / Brix) or more, preferably 6.0 ppm / Brix or more, and more preferably 7.0 ppm / Brix or more in the heat-treated malt peptide, respectively. These upper limits are 50.0 ppm / Brix or less, preferably 40.0 ppm / Brix or less, more preferably 30.0 ppm / Brix or less, still more preferably about 20.0 ppm / Brix or less.

4. Composition for lowering blood pressure and composition for suppressing increase in blood pressure One aspect of the present invention is a composition for lowering blood pressure containing a heat-treated plant-derived peptide as an active ingredient. The present invention is also a composition for suppressing an increase in blood pressure, which contains a heat-treated plant-derived peptide as an active ingredient.

The content of the heat-treated plant-derived peptide in the composition of the present invention is not particularly limited as long as the desired effect of the present invention can be obtained in consideration of its administration form, administration method and the like. Absent. For example, the content of the heat-treated plant-derived peptide is 0.10% by weight or more, preferably 0.20% by weight or more, more preferably 0.40% by weight or more, based on the total weight of the composition of the present invention. .. The content of the heat-treated plant-derived peptide is 50% by weight or less, preferably 10% by weight or less, more preferably 5.0% by weight or less, based on the total weight of the composition of the present invention. Typically, the content of the heat-treated plant-derived peptide is 0.10% by weight to 50% by weight, preferably 0.20% by weight to 10% by weight, more preferably, based on the total weight of the composition of the present invention. Is 0.4% by weight to 5.0% by weight. Unless otherwise specified, "% by weight" as used in the present specification means weight / weight (w / w).

4-1. Other Ingredients The composition of the present invention may contain any additive and any commonly used ingredient in addition to the heat-treated plant-derived peptide, depending on its form. Examples of these additives and / or ingredients include physiologically active ingredients such as vitamins, minerals, nutritional ingredients, and fragrances, as well as excipients, binders, emulsifiers, and tensioning agents that are added to the formulation. Isotonic agents), buffers, solubilizers, preservatives, stabilizers, antioxidants, colorants, coagulants, coatings and the like, but are not limited thereto.

4-2. Uses By ingesting a composition containing the above-mentioned plant-derived peptide heat-treated product as an active ingredient, blood pressure can be lowered, and thereby hypertension and diseases caused by hypertension can be improved. Furthermore, by ingesting the composition containing the above-mentioned heat-treated plant-derived peptide as an active ingredient, an increase in blood pressure can be suppressed, and as a result, hypertension can be prevented. In the present invention, the disease caused by hypertension is not particularly limited, and examples thereof include stroke, heart disease, and renal failure. In addition, stroke includes cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage and the like, and heart disease includes angina pectoris, myocardial infarction, cardiac hypertrophy, heart failure and the like. Therefore, by ingesting the composition containing the above-mentioned plant-derived peptide heat-treated product as an active ingredient, strokes such as cerebral infarction, cerebral hemorrhage, and subarachnoid hemorrhage, and heart diseases such as angina, myocardial infarction, cardiac hypertrophy, and heart failure , And diseases caused by hypertension such as renal failure can be prevented or ameliorated.

The composition of the present invention is, for example, a raw material containing a plant-derived peptide heat-treated product, such as a solvent, a dispersant, an emulsifier, a buffer, a stabilizer, an excipient, a binder, a disintegrant, or a lubricant, if desired. Can be formulated into solid preparations such as tablets, granules, powders, powders or capsules, or liquid preparations such as ordinary liquids, suspensions or emulsions according to known methods. These compositions can be taken as they are with water or the like. In addition, it can be used as a raw material for pharmaceuticals, for example, after being prepared in a form that can be easily blended (for example, in powder form or granule form).

The present invention can be provided in the form of an agent as an example, but is not limited to this form. The agent can be provided as it is as a composition or as a composition containing the agent. As an example, it can be provided in the form of a medicine or the like, but it is not limited to this form. Examples of the composition of the present invention include, but are not limited to, pharmaceutical compositions, food and drink compositions, food compositions, beverage compositions, cosmetic compositions and the like. Non-limiting examples of food compositions include functional foods, health supplements, nutritionally functional foods, special purpose foods, foods for specified health uses, nutritional supplements, dietary foods, health foods, supplements, food additives, etc. Can be mentioned.

The composition of the present invention can be applied to either therapeutic use (medical use) or non-therapeutic use (non-medical use). Specific examples include its use as pharmaceuticals, quasi-drugs, cosmetics, etc., and although it does not belong to these under the Pharmaceutical Affairs Law, it has the effect of lowering blood pressure, suppressing the rise in blood pressure, and raising blood pressure. The effect of slowing down the blood pressure, the effect of suppressing a sudden rise in blood pressure when waking up, the effect of preventing hypertension, the effect of improving hypertension, the effect of protecting renal function, the effect of improving renal function, etc. Use as an implicitly appealing composition can be mentioned.

In another aspect, the present invention relates to the blood pressure lowering composition, which is labeled with a function exerted by lowering blood pressure. Such indications or functional indications are not particularly limited, but include, for example, "lowering blood pressure", "expecting a decrease in blood pressure", "preventing hypertension", "helping to improve hypertension", and "renal function". Improve ”and so on.

The present invention may be the composition for suppressing an increase in blood pressure, which is labeled with a function exerted by suppressing the increase in blood pressure. Such display or function display is not particularly limited, but for example, "suppresses the rise in blood pressure", "slows the rise in blood pressure", "suppresses the sudden rise in blood pressure when waking up", "hypertension". Examples include "preventing disease", "helping to improve hypertension", "protecting renal function", and "improving renal function".

In the present invention, indications such as the indication and the function indication may be attached to the composition itself, or may be attached to the container or packaging of the composition.

The composition of the present invention can be ingested by an appropriate method according to its form. Examples of the ingestion method include internal use (oral use), external use, injection, and the like, but the method is not particularly limited as long as the desired effect of the present invention is exhibited. In addition, in this specification, "ingestion" is used as including all aspects such as ingestion, ingestion, and drinking.

The applied amount of the composition of the present invention is timely set according to its form, administration method, purpose of use and age, body weight, and symptom of the patient or animal to be administered, and is not constant. The effective human intake of the heat-treated plant-derived peptide according to the present invention is not constant, but is, for example, preferably 500 mg or more, more preferably 1000 mg or more per day for a human having a body weight of 50 kg. In addition, administration may be performed once or in several divided doses within a day within a desired dose range. The administration period is also arbitrary. The effective human intake of the plant-derived peptide heat-treated product means the intake of the plant-derived peptide heat-treated product showing an effective effect in humans.

The application target of the agent of the present invention is preferably human, but it is applied to domestic animals such as cows, horses and goats, pet animals such as dogs, cats and rabbits, and experimental animals such as mice, rats, guinea pigs and monkeys. There may be. When administered to animals other than humans, the amount used per day for about 20 g per rat is the content of the active ingredient in the composition, the condition, body weight, sex, age, etc. of the target person. Generally, the dose of the heat-treated plant-derived peptide product is preferably 100 mg / kg or more, more preferably 1000 mg / kg or more, although it depends on the conditions of.

5. Use of a plant-derived peptide heat-treated product for lowering blood pressure, and use of a plant-derived peptide heat-treated product for suppressing an increase in blood pressure One aspect of the present invention is use for lowering blood pressure of a plant-derived peptide heat-treated product. .. Further, the present invention may be used for suppressing an increase in blood pressure of a plant-derived peptide heat-treated product.

The use of the plant-derived peptide heat-treated product of the present invention includes, for example, prevention or amelioration of hypertension, and prevention or amelioration of various diseases caused by hypertension such as stroke, heart disease, and renal failure. Included, but not limited to. In addition, the use is a human or non-human animal use, and may be a therapeutic use or a non-therapeutic use. Here, "non-therapeutic" is a concept that does not include medical treatment, that is, treatment of the human body by treatment.

6. A method for lowering blood pressure and a method for suppressing an increase in blood pressure One aspect of the present invention comprises administering a therapeutically effective amount of a heat-treated plant-derived peptide as an active ingredient to a subject in need of lowering blood pressure. It is a way to lower it. Further, the present invention may be a method for suppressing an increase in blood pressure, which comprises administering a therapeutically effective amount of a heat-treated plant-derived peptide as an active ingredient to a subject who needs to suppress the increase in blood pressure.

The subject requiring blood pressure lowering is the same as the subject to be administered with the blood pressure lowering composition of the present invention, and the subject requiring suppression of blood pressure increase is the subject of the composition for suppressing blood pressure increase of the present invention. It is the same as the administration subject.

Further, in the present specification, the therapeutically effective amount is an amount capable of lowering blood pressure when the plant-derived peptide heat-treated product of the present invention is ingested by the subject as compared with a subject not ingested. It is the amount that can suppress the rise in blood pressure. The specific effective amount is set in a timely manner depending on the administration form, administration method, purpose of use, age, body weight, symptom, etc. of the subject, and is not constant.

In the method of the present invention, the heat-treated plant-derived peptide may be administered as it is or as a composition containing the heat-treated plant-derived peptide so as to obtain the therapeutically effective amount.

According to the method of the present invention, it is possible to lower blood pressure and suppress an increase in blood pressure without causing side effects.

Hereinafter, the present invention will be described in more detail with reference to Examples, but this does not limit the scope of the present invention. Those skilled in the art can modify and modify the method of the present invention in various ways, and these are also included in the scope of the present invention.

Example 1: Preparation of heat-treated soybean peptide product A heat-treated soybean peptide product was produced by using soybean peptide as a plant-derived peptide and treating it with high temperature and high pressure in a liquid. Specifically, 15 ml of distilled water was added to 3 g of soybean peptide (High Newt AM, manufactured by Fuji Oil Co., Ltd.), placed in an autoclave (manufactured by Tomy Seiko Co., Ltd.), and treated at 135 ° C., 0.31 MPa, and high temperature for 3 hours. Was added. The total amount of the cyclic peptide or its salt contained in the heat-treated soybean peptide thus obtained was 91386.43 μg / 100 g / Brix. Moreover, as a comparative example, a soybean peptide unheated product which was not subjected to high temperature and high pressure treatment was prepared using the same peptide.

Example 2: Antihypertensive effect of heat-treated soybean peptide using spontaneously hypertensive rats (SHR) The antihypertensive effect of the heat-treated soybean peptide (1 g / kg, 2 g / kg) prepared in Example 1 was evaluated. As a control group, the antihypertensive effect of a non-heated soybean peptide (2 g / kg) was also evaluated. The specific experimental method is shown below. After weighing the animals fasted overnight, systolic blood pressure was measured using a small animal non-heated non-invasive sphygmomanometer (MK-2000, Muromachi Kikai Co., Ltd.) (pre-value). After the measurement was completed, the administered substance was orally administered, and the systolic blood pressure of the rats was measured 2, 4, 6, 8 and 24 hours after the administration. Fasting was canceled after the measurement was completed 4 hours after administration. The obtained systolic blood pressure value was calculated as the amount of change (mmHg) with respect to the pre-value for each individual, and the average value and standard error of the amount of change were calculated for each group. The mean values of the significant differences between the groups were compared by the Tukey method. At that time, the significance level was set to a risk rate of 5% and 1%. The results are shown in FIG.

When the mean values of each group were compared by the Tukey's method at each time after administration, a significant difference of 10% or less in risk was observed only between the control group 6 hours after administration and the soybean peptide heat-treated product 2 g / kg administration group. (P = 0.07). In addition, the soybean peptide heat-treated product 1 g / kg administration group showed the same blood pressure transition as the non-heated product 2 g / kg administration group. From this, it was suggested that the heat-treated soybean peptide has an excellent antihypertensive effect as compared with the non-heated product, and is useful as an active ingredient of the composition for lowering blood pressure and the composition for suppressing increase in blood pressure.

The present invention contains a plant-derived peptide heat-treated product easily produced by high-temperature and high-pressure treatment as an active ingredient, and has a stronger effect than a known plant-derived peptide-containing material, such as a composition for lowering blood pressure or an increase in blood pressure. It provides an inhibitory composition. Therefore, the present invention provides a safe and effective new means for preventing or ameliorating diseases caused by hypertension such as hypertension, stroke, heart disease, and renal failure. Higher usability.

Claims (6)

A composition for lowering blood pressure or a composition for suppressing increase in blood pressure, wherein the total amount of the cyclic dipeptide or its salt contained in the composition is 20000 μg / 100 g / Brix or more, and the cyclic dipeptide is derived from soybean peptide. There, said composition. The composition for lowering blood pressure or the composition for suppressing increase in blood pressure according to claim 1, wherein the total amount of the cyclic dipeptide or a salt thereof is 30,000 μg / 100 g / Brix or more. The composition for lowering blood pressure or the composition for suppressing increase in blood pressure according to claim 1 or 2, which is for preventing or ameliorating hypertension. The composition for lowering blood pressure or the composition for suppressing increase in blood pressure according to claim 1 or 2, which is used for preventing or ameliorating stroke, heart disease, or renal failure. The composition for lowering blood pressure or the composition for suppressing an increase in blood pressure according to any one of claims 1 to 4, which is labeled with a function exerted by lowering blood pressure or suppressing an increase in blood pressure. Function indications are "lower blood pressure", "expect lower blood pressure", "suppress blood pressure rise", "moderate blood pressure rise", "suppress sudden rise in blood pressure when waking up" , "Preventing hypertension," "helping to improve hypertension," "protecting renal function," and "improving renal function," according to claim 5. The composition for lowering blood pressure or the composition for suppressing increase in blood pressure.

Images